Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma.

被引：0
|
作者：
Smith, JW
Ko, YJ
Dutcher, J
Hudes, G
Escudier, B
Motzer, R
Négrier, S
Duclos, B
Galand, L
Strauss, L
机构：
[1] Providence Portland Med Ctr, Earle Chiles Res Inst, Portland, OR USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Our Lady Mercy Canc Ctr, Bronx, NY USA
[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[5] Inst Gustave Roussy, Villejuif, France
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CHU Hautepierre, F-67098 Strasbourg, France
[9] Wyeth Ayerst Res, Paris, France
[10] Wyeth Ayerst Res, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4513
引用
收藏
页码：385S / 385S
页数：1
相关论文
共 50 条
  • [1] Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors.
    Haas, N. B.
    Lewis, N.
    Cohen, R. B.
    Malizzia, L.
    Einarson, M. B.
    Walker, M. A.
    Kim, T.
    Von Mehren, M.
    Hudes, G. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 137S - 137S
  • [2] A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias.
    Yee, KWL
    Garcia-Manero, G
    Thomas, D
    Ani, FRK
    Verstovsek, S
    Andreeff, M
    Dancey, JE
    Giles, FJ
    BLOOD, 2004, 104 (11) : 214B - 214B
  • [3] A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
    Fujisaka, Yasuhito
    Yamada, Yasuhide
    Yamamoto, Noboru
    Horiike, Atsushi
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 732 - 738
  • [4] A PHASE 2 STUDY OF SAFETY AND EFFICACY OF TEMSIROLIMUS (CCI-779) ADMINISTERED AS A SINGLE AGENT IN EAST ASIAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
    Sun, Y.
    Rha, S. Y.
    Lee, S.
    Guo, J.
    Ueda, T.
    Qin, S.
    Naito, S.
    Cincotta, M.
    Tokushige, K.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 290 - 290
  • [5] Population pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis of CCI-779 in patients with advanced renal cell cancer.
    Boni, JP
    Leister, C
    Bender, G
    Fitzpatrick, V
    Twine, N
    Stover, J
    Dorner, A
    Immermann, F
    Burczynski, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P41 - P41
  • [6] Low expression of surrogates for mTOR pathway activation predicts resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC).
    Cho, DC
    Signoretti, S
    Regan, M
    McDermott, D
    Polivy, A
    Youmans, A
    Stanbridge, E
    Atkins, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9133S - 9134S
  • [7] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    BLOOD, 2009, 114 (22) : 664 - 665
  • [8] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Atkins, MB
    Hidalgo, M
    Stadler, WM
    Logan, TF
    Dutcher, JP
    Hudes, GR
    Park, Y
    Lion, SH
    Marshall, B
    Boni, JP
    Dukart, G
    Sherman, ML
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 909 - 918
  • [9] Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    Merchan, J. R.
    Liu, G.
    Fitch, T.
    Picus, J.
    Qin, R.
    Pitot, H. C.
    Maples, W.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC
    Molina, Julian R.
    Mandrekar, Sumithra J.
    Rowland, Kendrith
    Reuter, Nicholas F.
    Jett, James R.
    Marks, Randolph
    Schild, Stevens E.
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S413 - S413
12345